Theresa M. Wewers
University of Veterinary Medicine Vienna
Internal medicineUrologyEndocrinologyBiopsyVascular endothelial growth factorPreeclampsiaKidney diseaseSoluble fms-like tyrosine kinase-1Diabetic nephropathyKidneyKidney transplantationPathogenesisEndothelial dysfunctionRenal fibrosisBlood volumeTyrosine kinaseIschemiaMedicine
2Publications
1H-index
5Citations
Publications 2
Newest
Soluble Fms-like tyrosine kinase (sFlt-1/sVEGFR1) is a natural occurring antagonist of vascular endothelial growth factor (VEGF). Despite being a secreted, soluble protein lacking cytoplasmic and transmembrane domains, sFlt-1 can act locally and be protective against excessive microenvironmental VEGF concentration, or exert autocrine functions independently of VEGF. Circulating sFlt-1 may indiscriminately affect endothelial function and the microvasculature on distant target organs. The clinical...
Source
#1Theresa M. WewersH-Index: 1
#2Anna B. MayerH-Index: 3
Last. Giovana Seno Di MarcoH-Index: 18
view all 12 authors...
Renal ischemia reperfusion injury (IRI) adversely affects clinical outcomes following kidney transplantation. Understanding the cellular mechanisms and the changes in gene/protein expression following IRI may help to improve these outcomes. Serum soluble fms-like tyrosine kinase 1 (sFlt-1), a circulating antiangiogenic protein, is increased in the first week following kidney transplantation. We evaluated the casual relationship of elevated sFlt-1 levels with renal microvascular dysfunction follo...
6 CitationsSource